Latest News

Why Elis is on investors’ radar today Elis (ENXTPA:ELIS) has drawn attention after recent share price pressure, with the stock down about 11% over the past month and slightly lower over the past 3 months. This has prompted fresh interest in its valuation. See our latest analysis for Elis. Despite the recent 11% 30 day share price decline and softer short term momentum, Elis still carries a 1 year total shareholder return of about 20% and an approximately 84% total shareholder return over 5...

DENTSPLY SIRONA (XRAY) is back in focus after recent coverage highlighted soft constant currency revenue growth and diminishing returns on capital, putting management’s past and current decisions under a brighter spotlight for investors. See our latest analysis for DENTSPLY SIRONA. The recent concerns around soft constant currency revenue growth and weaker returns on capital sit against a share price of US$11.47 and a 1 month share price return of a 22% decline, with a 1 year total...

AIA Group (SEHK:1299) has drawn investor attention after recent share price moves, with the stock showing mixed returns over the past month and past 3 months, alongside reported revenue of $26,215m and net income of $6,234m. See our latest analysis for AIA Group. Over the past year, AIA Group’s share price return has been more muted than its 47.66% total shareholder return. This suggests dividends and other distributions have played a meaningful role even as recent short-term share price...

M3 (TSE:2413) has completed its previously announced share buyback, repurchasing 11,649,800 shares, or 1.72% of its stock, for ¥19,999.9 million. This move returns capital directly to shareholders. See our latest analysis for M3. The buyback completion comes after a period of weaker momentum, with the 30-day share price return of 8.35% and 90-day share price return of 25.52% contributing to a 1-year total shareholder return of 7.49% and a 5-year total shareholder return of 79.73%. If you are...

Hershey stock in focus after recent performance shifts Hershey (HSY) has drawn investor attention after a recent stretch where the stock showed a decline of about 9% over the past month, but a gain of roughly 17% over the past 3 months. See our latest analysis for Hershey. At a share price of $213.73, Hershey’s recent 1 day and 90 day share price returns of 1.57% and 17.31% contrast with a 9.69% decline in 3 year total shareholder return. This suggests momentum has firmed up recently while...

How RBC Bearings' Valuation Stacks Up Against Its Market Price With RBC Bearings' share price around US$532.25, many investors are asking the same question: is the stock pricing in too much optimism, or are markets still underestimating its potential? Recent returns are mixed, with a 0.9% decline over the last 7 days and a 7.6% decline over the last 30 days, set against a 16.0% gain year to date and a 65.4% return over the past year. These moves sit in the context of RBC Bearings' longer term...

In March 2026, Tripadvisor announced a cooperation agreement with activist investor Starboard Value that added Dhiren Fonseca and Andrew F. Cates to its Board, expanded the Board to ten directors, and set the stage for two additional Starboard-recommended nominees at the 2026 Annual Meeting. This agreement, alongside the planned retirement of long-time directors Greg Maffei and Albert Rosenthaler, signals a meaningful reshaping of Tripadvisor’s governance and potential reassessment of its...

Consumer sentiment shock hits Monarch Casino & Resort (MCRI) The sharp drop in the latest University of Michigan consumer sentiment survey sent several consumer discretionary names lower, and Monarch Casino & Resort (MCRI) fell 2.6% in the afternoon session. See our latest analysis for Monarch Casino & Resort. Beyond today’s consumer sentiment shock, Monarch’s recent weakness, including a 3.33% one day share price decline and softer short term returns, contrasts with its much stronger 1 year...

Event driven snapshot of Sarepta Therapeutics Sarepta Therapeutics (SRPT) is back on investor radar after recent share price swings, including a 13% gain over the past week and a 19% move over the past month, against a weaker one year return. See our latest analysis for Sarepta Therapeutics. The recent 19.2% 30 day share price return contrasts with a weaker 1 year total shareholder return of a 68.7% decline, suggesting that short term momentum has improved while longer term holders remain...

Palantir Technologies (NasdaqGS:PLTR) has expanded its partnership with Bain & Company to bring its AIP and Foundry platforms to more large enterprise clients worldwide. The company has recently rolled out new commercial AI deployments, including work with Moder and Freedom Mortgage in the mortgage sector. Palantir is also working with Keel Holdings on Navy ShipOS, applying operational AI to naval shipbuilding and related workflows. For investors tracking enterprise AI, Palantir sits at the...

Credit Acceptance Corporation recently appointed former Deutsche Telekom and T-Mobile executive Steffen Schumann as its Chief Business Officer, reporting to CEO Vinayak Hegde, with responsibilities spanning enterprise business planning, pricing strategy, advanced analytics, and dealer scorecarding. The hire underscores Credit Acceptance’s effort to tighten execution and translate analytics-driven insights into actions, at a time when management is seeing early signs of operational stability...

If you are wondering whether DoorDash is priced attractively or already reflects too much optimism, this article breaks down what the current share price may be implying about the company. DoorDash shares recently closed at US$146.60, after a 7 day return of an 8.4% decline, a 30 day return of a 16.9% decline, and a year to date return of a 33.3% decline. The 1 year return sits at a 19.8% decline and the 3 year return at 129.3%. These shifts in returns have put more attention on how the...

Glanbia (ISE:GL9) has drawn attention after recent share price swings, with a 1 day decline alongside mixed short term returns and stronger figures over the past 3 months and year. This has prompted closer focus on fundamentals. See our latest analysis for Glanbia. At a share price of €16.81, Glanbia’s shorter term share price returns have been mixed, but a 90 day share price return of 15.45% and 1 year total shareholder return of 69.8% suggest momentum has been building over time. If...

Why recent operating pressure at Rogers (ROG) matters for shareholders Recent reports of 5.5% annual sales declines for two straight years and a 7.2 percentage point drop in operating margin put Rogers (ROG) in focus for investors watching earnings power and share price resilience. See our latest analysis for Rogers. Despite the operating pressure, Rogers has seen momentum build recently, with a 16.9% 90 day share price return and a 61.9% 1 year total shareholder return, although longer term...

Murphy Oil recently increased its quarterly dividend by 8% to US$0.35 per share, continued repurchasing stock under its remaining US$550.00 million authorization, and highlighted cost efficiencies including a 20% year-over-year reduction in lease operating expenses and lower Eagle Ford drilling costs. The company’s Vietnamese assets have shifted from a speculative position to a clearer growth platform, with Lac Da Vang first oil targeted for late 2026 and additional Hai Su Vang appraisal...

Why JinkoSolar Holding (NYSE:JKS) is on investor radars today JinkoSolar Holding (NYSE:JKS) has drawn investor attention after recent share price moves, with the stock closing at US$25.29 and showing mixed returns over the past year and over the past 3 months. See our latest analysis for JinkoSolar Holding. For JinkoSolar, short term share price momentum has been positive, with a 7 day share price return of 5.77%. The year to date share price return is a 9.48% decline, and the 1 year total...

Earlier in March 2026, Okta announced Okta for AI Agents, a new platform launching on April 30, 2026 to help enterprises discover, register, and govern both sanctioned and shadow AI agents as first-class identities across their environments. This move extends Okta’s identity platform into managing non-human AI agents, potentially making it a core infrastructure layer for organizations scaling AI-powered operations and security controls. We’ll now examine how Okta for AI Agents could...

As tensions in the Middle East have led to fluctuations across Gulf markets, investors are closely monitoring developments that might impact regional economies. In such a climate, penny stocks—typically representing smaller or newer companies—remain an intriguing area of investment despite their somewhat outdated label. These stocks can offer a blend of affordability and growth potential, especially when backed by strong financials, making them worth considering for those looking beyond...

In recent times, Middle Eastern markets have experienced a degree of volatility, with most Gulf indices easing due to geopolitical tensions, notably the potential for broader conflict involving Iran. Despite these challenges, opportunities remain for investors willing to explore lesser-known stocks that exhibit resilience and growth potential in such uncertain environments. Identifying promising stocks often involves looking beyond current market sentiment to find companies with strong...

AsiaInfo Technologies Limited's ( HKG:1675 ) earnings announcement last week didn't impress shareholders. Despite the...

As you might know, Jiumaojiu International Holdings Limited ( HKG:9922 ) last week released its latest annual, and...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Some investors may be wondering if Eli Lilly is still worth its current price, or if the recent run has already baked in too much optimism. The stock closed at US$878.24, with returns of a 3.5% decline over 7 days, a 16.5% decline over 30 days, an 18.7% decline year to date, a 7.1% gain over 1 year, a 156.0% gain over 3 years and a very large gain over 5 years. Recent headlines have focused on Eli Lilly's role in high profile drug categories, including weight management and other blockbuster...

Structure Therapeutics recently reported positive topline Phase 2 ACCESS II and related study data for aleniglipron, an oral once-daily GLP-1 receptor agonist for people living with obesity or overweight, showing clinically meaningful and statistically significant weight loss alongside a tolerability profile consistent with its drug class. A particularly interesting aspect is that aleniglipron’s weight loss efficacy was described as comparable to injectable GLP-1 therapies while using an...